Mechanisms of Immune Tolerance in Leukemia and Lymphoma

Trends Immunol. 2017 Jul;38(7):513-525. doi: 10.1016/j.it.2017.04.004. Epub 2017 May 13.

Abstract

The mechanisms through which immune responses are generated against solid cancers are well characterized and knowledge of the immune evasion pathways exploited by these malignancies has grown considerably. However, for hematological cancers, which develop and disseminate quite differently than solid tumors, the pathways that regulate immune activation or tolerance are less clear. Growing evidence suggests that, while numerous immune escape pathways are shared between hematological and solid malignancies, several unique pathways are exploited by leukemia and lymphoma. Below we discuss immune evasion mechanisms in leukemia and lymphoma, highlighting key differences from solid tumors. A more complete characterization of the mechanisms of immune tolerance in hematological malignancies is critical to inform the development of future immunotherapeutic approaches.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigen-Presenting Cells / immunology*
  • Antigen-Presenting Cells / pathology
  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / immunology
  • Gene Expression Regulation
  • Humans
  • Immune Evasion*
  • Immune Tolerance*
  • Immunotherapy / methods*
  • Leukemia / genetics
  • Leukemia / immunology*
  • Leukemia / pathology
  • Leukemia / therapy
  • Lymphoma / genetics
  • Lymphoma / immunology*
  • Lymphoma / pathology
  • Lymphoma / therapy
  • Programmed Cell Death 1 Receptor / genetics
  • Programmed Cell Death 1 Receptor / immunology
  • Receptors, Pattern Recognition / genetics
  • Receptors, Pattern Recognition / immunology
  • Signal Transduction
  • T-Lymphocytes / immunology
  • T-Lymphocytes / pathology

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Pattern Recognition